Published in Gastroenterology on April 01, 2003
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
Disorders of sodium balance. BMJ (2006) 3.84
Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer (2007) 1.84
Guidelines on the management of ascites in cirrhosis. Gut (2006) 1.81
Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan. Dig Dis Sci (2012) 1.47
Aquaporins in kidney pathophysiology. Nat Rev Nephrol (2010) 1.18
Vaptans: A new option in the management of hyponatremia. Int J Appl Basic Med Res (2012) 1.11
Hyponatraemia in clinical practice. Postgrad Med J (2007) 1.10
Conivaptan: a step forward in the treatment of hyponatremia? Ther Clin Risk Manag (2008) 0.92
Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol (2013) 0.91
Current and future treatment options in SIADH. NDT Plus (2009) 0.90
Vasopressin and aquaporin 2 in clinical disorders of water homeostasis. Semin Nephrol (2008) 0.90
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol (2011) 0.89
Review of Tolvaptan's Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions. J Clin Med (2014) 0.88
Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia. Therap Adv Gastroenterol (2012) 0.86
Improving survival in decompensated cirrhosis. Int J Hepatol (2012) 0.86
The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials. BMC Gastroenterol (2015) 0.86
Conivaptan: Evidence supporting its therapeutic use in hyponatremia. Core Evid (2010) 0.84
Hyponatremia in cirrhosis: pathophysiology and management. World J Gastroenterol (2015) 0.84
The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82
Hyponatraemia and cirrhosis. Gastroenterol Rep (Oxf) (2014) 0.82
Aquaporin-2 urinary excretion in cirrhosis: relationship to vasopressin and nitric oxide. Dig Dis Sci (2009) 0.80
Hyponatremia as an independent prognostic factor in patients with terminal cancer. Support Care Cancer (2014) 0.80
Child-Na score: a predictive model for survival in cirrhotic patients with symptomatic portal hypertension treated with TIPS. PLoS One (2013) 0.80
Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention. Br J Pharmacol (2005) 0.79
Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int (2008) 0.79
Vaptans and hyponatremia in critical patients. Transl Med UniSa (2012) 0.78
Dynamic regulation and dysregulation of the water channel aquaporin-2: a common cause of and promising therapeutic target for water balance disorders. Clin Exp Nephrol (2013) 0.78
Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites? World J Gastroenterol (2015) 0.78
Molecular mechanisms of clinical concentrating and diluting disorders. Prog Brain Res (2008) 0.77
Management of hyponatremia. CMAJ (2013) 0.77
Hyponatremia in Patients with Cirrhosis of the Liver. J Clin Med (2014) 0.76
Progress in treatment of massive ascites and hepatorenal syndrome. World J Gastroenterol (2006) 0.75
Renal dysfunction in patients with chronic liver disease. Electrolyte Blood Press (2009) 0.75
Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia: A Meta-Analysis. Medicine (Baltimore) (2016) 0.75
Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis. World J Hepatol (2014) 0.75
AVP receptor antagonists in patients with CHF. Heart Fail Rev (2008) 0.75
Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the Emergency Department. Intern Emerg Med (2016) 0.75
Performance of Disease-Specific Scoring Models in Intensive Care Patients with Severe Liver Diseases. J Clin Diagn Res (2017) 0.75
Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach. Dig Dis Sci (2017) 0.75
Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf) (2017) 0.75
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med (2006) 10.63
Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med (2002) 4.54
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med (2006) 4.33
Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med (2003) 3.61
Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology (2010) 3.45
A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol (2013) 3.41
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology (2007) 3.19
Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 3.13
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol (2014) 3.06
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology (2002) 2.86
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology (2008) 2.69
Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology (2012) 2.46
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis (2010) 2.41
A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol (2008) 2.35
Management of patients with cirrhosis awaiting liver transplantation. Gut (2010) 2.34
A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.32
Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.30
Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology (2005) 2.29
Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest (2003) 2.25
Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology (2010) 2.22
Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.22
Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol (2012) 2.20
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant (2014) 2.10
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med (2013) 2.09
MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut (2007) 2.09
Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology (2012) 2.03
Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology (2003) 2.01
Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol (2009) 1.96
Unraveling the structure of DNA during overstretching by using multicolor, single-molecule fluorescence imaging. Proc Natl Acad Sci U S A (2009) 1.95
Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology (2012) 1.92
Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology (2006) 1.85
Strategies to prevent clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.84
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol (2004) 1.82
Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.81
Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int (2012) 1.77
Prospects for urinary proteomics: exosomes as a source of urinary biomarkers. Nephrology (Carlton) (2005) 1.77
Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology (2009) 1.76
Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol (2002) 1.74
Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology (2006) 1.71
Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl (2009) 1.69
Dry cough in a CAPD patient. Nephrol Dial Transplant (2003) 1.68
Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.66
Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology (2006) 1.64
Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology (2010) 1.61
Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology (2014) 1.60
MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology (2005) 1.58
Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology (2003) 1.57
Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology (2004) 1.56
Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol (2012) 1.55
Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology (2005) 1.53
Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut (2012) 1.51
Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole. Clin Sci (Lond) (2003) 1.49
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl (2011) 1.44
Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol (2007) 1.44
Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology (2006) 1.41
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis (2008) 1.40
Re-induction of hyponatremia after rapid overcorrection of hyponatremia reduces mortality in rats. Kidney Int (2009) 1.39
Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology (2005) 1.35
Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. J Hepatol (2005) 1.34
Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol (2006) 1.32
Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal (2005) 1.31
Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology (2010) 1.29
Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes (2005) 1.25
PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis (2005) 1.25
Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci (2009) 1.23
Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother (2013) 1.21
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology (2010) 1.21
Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis (2008) 1.21
Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology (2002) 1.20
The biliary epithelium gives rise to liver progenitor cells. Hepatology (2014) 1.19
Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol (2011) 1.18
Minocycline protects against neurologic complications of rapid correction of hyponatremia. J Am Soc Nephrol (2010) 1.18
Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet. Kidney Int (2011) 1.18
Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology (2010) 1.18
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care (2004) 1.17
Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol (2009) 1.17
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Intensive Care Med (2014) 1.17
Revealing the competition between peeled ssDNA, melting bubbles, and S-DNA during DNA overstretching using fluorescence microscopy. Proc Natl Acad Sci U S A (2013) 1.14
Clinical management of SIADH. Ther Adv Endocrinol Metab (2012) 1.13
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med (2009) 1.13
Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol (2012) 1.12
The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant (2003) 1.10
Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis (2004) 1.09
Vasopressin Antagonists. N Engl J Med (2015) 1.09
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol (2011) 1.09
Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol (2005) 1.08
Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. J Hepatol (2010) 1.08
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother (2008) 1.06
Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology (2003) 1.05
Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int (2010) 1.01
Thiazides: do they kill? Nephrol Dial Transplant (2005) 1.01
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J (2008) 1.01
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut (2011) 1.00
LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol (2012) 0.98